Key Points
- CEO Martine Rothblatt sold 9,500 United Therapeutics shares at an average price of $501.39, generating $4.76 million. The transaction reduced her direct ownership by 2.84% to 324,443 shares.
- United Therapeutics reported quarterly EPS of $7.27, exceeding the $6.86 consensus estimate, while revenue of $783.3 million fell short of expectations and declined 1.9% year over year.
- Institutional investors own 94.08% of UTHR, and analysts maintain a “Moderate Buy” consensus with an average price target of $646, above the stock’s reported $497.27 opening price.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $501.39, for a total value of $4,763,205.00. Following the sale, the chief executive officer directly owned 324,443 shares of the company's stock, valued at $162,672,475.77. This trade represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
United Therapeutics Stock Performance
UTHR opened at $497.27 on Friday. United Therapeutics Corporation has a one year low of $402.50 and a one year high of $609.35. The company has a market cap of $21.33 billion, a P/E ratio of 17.79, a PEG ratio of 2.50 and a beta of 0.56. The business's 50-day simple moving average is $516.53 and its 200-day simple moving average is $540.64.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping the consensus estimate of $6.86 by $0.41. The firm had revenue of $783.30 million during the quarter, compared to analysts' expectations of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm's revenue was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $6.41 earnings per share. As a group, analysts predict that United Therapeutics Corporation will post 26.21 earnings per share for the current fiscal year.
Institutional Investors Weigh In On United Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in UTHR. Talon Private Wealth LLC increased its position in United Therapeutics by 31.8% in the 2nd quarter. Talon Private Wealth LLC now owns 6,753 shares of the biotechnology company's stock valued at $3,659,000 after acquiring an additional 1,630 shares during the period. Sequoia Financial Advisors LLC lifted its position in United Therapeutics by 4.4% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 2,530 shares of the biotechnology company's stock worth $1,371,000 after acquiring an additional 106 shares during the period. Tidal Investments LLC lifted its position in United Therapeutics by 1.6% during the 2nd quarter. Tidal Investments LLC now owns 34,012 shares of the biotechnology company's stock worth $18,429,000 after acquiring an additional 547 shares during the period. Archford Capital Strategies LLC acquired a new stake in United Therapeutics during the 2nd quarter worth approximately $552,000. Finally, Engineers Gate Manager LP purchased a new position in shares of United Therapeutics in the 2nd quarter valued at approximately $2,524,000. 94.08% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on UTHR. TD Cowen restated a "buy" rating on shares of United Therapeutics in a report on Thursday, May 21st. Royal Bank Of Canada decreased their target price on United Therapeutics from $704.00 to $677.00 and set an "outperform" rating for the company in a research report on Thursday, August 6th. Bank of America dropped their price target on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating on the stock in a research note on Friday, July 10th. Weiss Ratings cut United Therapeutics from a "buy (b)" rating to a "buy (b-)" rating in a research note on Thursday, August 27th. Finally, Morgan Stanley set a $515.00 price objective on United Therapeutics in a report on Thursday, August 6th. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, United Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $646.00.
View Our Latest Report on UTHR
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company's products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.
United Therapeutics' PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
